<table style="border:1px solid #adadad; background-color: #F3F1EC; color: #666666; padding:8px; -webkit-border-radius:4px; border-radius:4px; -moz-border-radius:4px; line-height:16px; margin-bottom:6px;" width="100%">
        <tbody>
                <tr>
                        <td><span style="font-family:Helvetica, sans-serif; font-size:20px;font-weight:bold;">Mind & Brain News -- ScienceDaily</span></td>
                </tr>
                <tr>
                        <td> </td>
                </tr>
        </tbody>
</table>
<table style="font:13px Helvetica, sans-serif; border-radius:4px; -moz-border-radius:4px; -webkit-border-radius:4px; background-color:#fff; padding:8px; margin-bottom:6px; border:1px solid #adadad;" width="100%">
        <tbody>
                <tr>
                        <td><a href="https://www.sciencedaily.com/releases/2025/12/251222044104.htm" style="font-family:Helvetica, sans-serif; letter-spacing:-1px;margin:0;padding:0 0 2px;font-weight: bold;font-size: 19px;line-height: 20px;color:#222;">This cancer-fighting molecule took 50 years to build</a>
                        <div style="font-family:Helvetica, sans-serif; text-align:left;color:#999;font-size:11px;font-weight:bold;line-height:15px;">Dec 22nd 2025, 10:36</div>

                        <div style="font-family:Helvetica, sans-serif; color:#494949;text-align:justify;font-size:13px;">
                        <p>MIT scientists have achieved the first-ever lab synthesis of verticillin A, a complex fungal compound discovered in 1970. Its delicate structure stalled chemists for decades, despite differing from related molecules by only two atoms. With the synthesis finally complete, researchers created new variants that showed strong activity against a rare pediatric brain cancer. The breakthrough could unlock an entire class of previously unreachable cancer-fighting molecules.</p>
                        </div>

                        <div style="font-family:Helvetica, sans-serif; font-size:13px; text-align: center; color: #666666; padding:4px; margin-bottom:2px;"></div>
                        </td>
                </tr>
        </tbody>
</table>
<table style="font:13px Helvetica, sans-serif; border-radius:4px; -moz-border-radius:4px; -webkit-border-radius:4px; background-color:#fff; padding:8px; margin-bottom:6px; border:1px solid #adadad;" width="100%">
        <tbody>
                <tr>
                        <td><a href="https://www.sciencedaily.com/releases/2025/12/251222080119.htm" style="font-family:Helvetica, sans-serif; letter-spacing:-1px;margin:0;padding:0 0 2px;font-weight: bold;font-size: 19px;line-height: 20px;color:#222;">A new drug could stop Alzheimer’s before memory loss begins</a>
                        <div style="font-family:Helvetica, sans-serif; text-align:left;color:#999;font-size:11px;font-weight:bold;line-height:15px;">Dec 22nd 2025, 08:11</div>

                        <div style="font-family:Helvetica, sans-serif; color:#494949;text-align:justify;font-size:13px;">
                        <p>New research suggests Alzheimer’s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early damage in mice and reduces inflammation linked to disease progression. The treatment was given before symptoms appeared, targeting the disease at its earliest stage. Researchers say this approach could reshape how Alzheimer’s is prevented and treated.</p>
                        </div>

                        <div style="font-family:Helvetica, sans-serif; font-size:13px; text-align: center; color: #666666; padding:4px; margin-bottom:2px;"></div>
                        </td>
                </tr>
        </tbody>
</table>
<p><strong>Forwarded by:<br />
Michael Reeder LCPC<br />
Baltimore, MD</strong></p>

<p><strong>This information is taken from free public RSS feeds published by each organization for the purpose of public distribution. Readers are linked back to the article content on each organization's website. This email is an unaffiliated unofficial redistribution of this freely provided content from the publishers. </strong></p>

<p> </p>

<p><s><small><a href="#" style="color:#ffffff;"><a href='https://blogtrottr.com/unsubscribe/565/QbcxgL'>unsubscribe from this feed</a></a></small></s></p>